EN
SLU-PP-332
500 mcg · Tablets
SLU-PP-332 is a small synthetic molecule rather than a peptide. Its placement in the catalogue does not replace close examination of experimental evidence.
- SLU-PP-332
- 500 mcg per tablet
- Tablets
- Batch information as labelled
- Storage according to product label
- Shipping across the EU
COA batch
Vials and pens of the same compound and strength use the same material batch. The report covers the starting material.
Support through delivery
Your satisfaction comes first. If your parcel is lost in transit, we send a replacement free of charge. Our support team also helps personally with damaged or incorrect items. Details & contact
Batch, shipping & returns
Find the batch identification on the product packaging and match it to a relevant published lab report. An analytical result applies only to the sample, batch and test method named in that report.
Vials can be returned with their protective cap unopened and intact. We do not offer voluntary returns for pens because possible tampering after delivery cannot reliably be ruled out. Statutory withdrawal and defect rights remain unaffected. Contact us with your order number and we will explain the appropriate process. Returns & claims.
- Product
- SLU-PP-332
- Format
- Tablets
- Per tablet
- 500 mcg
- Composition
- SLU-PP-332
- Storage
- According to label and batch documentation
- Quality documentation
- Only as documented in the relevant published batch report
- Pack content
- 100 tablets
- SKU
- slu-pp-332-500mcg
SLU-PP-332: ERR research and the tablet label
SLU-PP-332 is a small synthetic molecule rather than a peptide. Its placement in the catalogue does not replace close examination of experimental evidence.
What the ERR study investigates
A 2023 paper examined a synthetic agonist of estrogen-related receptors ERRα, ERRβ and ERRγ in preclinical models. Findings included metabolism-related gene programmes and experimental functional measurements.
Preclinical findings and product format
The experimental design determines what can be concluded. Cell and animal findings do not justify an efficacy promise for a tablet sold in a catalogue. In particular, an experimental exposure route does not establish oral availability of a particular formulation.
Reading 500 mcg per tablet
The bottle contains 100 tablets with a nominal 500 mcg each. Arithmetically, this is 0.5 mg per tablet and 50 mg total per bottle. This calculation describes content rather than giving use instructions or stating absorbed content.
Tablets need their own quality data
Alongside compound identity, content uniformity, excipients and tablet stability matter. Purity data for an ingredient do not automatically establish the properties of every finished tablet. Suitable testing of the finished product is needed.
Read the full research article →
